top of page

Biosenta Announces Successful Launch of Bench Scale Production Plant and Exceeding Expectations of Tri-Filler™ Particle Encapsulation Technology

[TORONTO, ONTARIO / CALGARY, ALBERTA] March 27, 2024 — Biosenta Inc. ("Biosenta" or the "Company") (CSE: ZRO) is pleased to announce a significant milestone in its technological and operational advancements with the successful construction and operation of a bench scale production plant. The results from this production not only surpassed our expectations, but also showcased that our patented Tri-Filler™ antimicrobial technology is ready for accelerated development and scaling towards industrial manufacturing applications.

Operational Success and Optimizations

Biosenta has successfully constructed and commenced operations of a bench scale production plant, showcasing our capability to produce up to 15 kilograms of Tri-Filler™ daily. This marks a significant scale-up from our previous capacity, which was limited to smaller quantities for lab testing purposes only.

CEO's Perspective

This is an amazing achievement by Dr. Maen Husein and group. The optimized particles are now being tested in industrial manufacturing processes,” says Am Gill, CEO of Biosenta Inc. This development is not just a step forward in antimicrobial technology but also a testament to our team's dedication and innovative spirit.

Promising Results and Future Directions

According to Dr. Maen Husein, “The initial runs of Tri-Filler™ have delivered beyond expectations, with particle quality surpassing pre-established benchmarks. These results validate both the antimicrobial efficacy of the particles and the design of the manufacturing unit.”  Next steps involve operation of the bench scale plant, aiming to produce sufficient Tri-Filler™ for pilot runs in various industrial processes such as coatings, concrete, drywall, plastics, and other vast materials in the construction industry.  Plans for a commercial scale plant will follow.

Research Collaboration with the University of Calgary

In partnership with the University of Calgary, further investigations will assess the performance of the bench scale plant against diverse input grades. This collaboration is crucial for refining the industrial scale plant's optimization, paving the way for broader commercial applications of Tri-Filler™ technology.


Looking Ahead

The construction of an industrial scaleup plant is under active consideration, with further details and timelines to be shared. This move will significantly enhance our production capabilities and impact across multiple industries.


About Biosenta Inc.

Biosenta Inc. is dedicated to the discovery, development, and commercialization of innovative antimicrobial products derived from its proprietary Tri-Filler™ technology. Based in Toronto, Ontario, Biosenta aims to revolutionize the way we combat microbes, offering solutions that are not only effective but also environmentally friendly and sustainable.


For further inquiries, please contact:

●       Am Gill, President and CEO, Biosenta Inc.

●       Email: 

●       Phone:  416-410-2019

Biosenta is poised for a future where our antimicrobial technology plays a pivotal role in promoting public health and safety. Stay tuned for more updates as we continue to innovate and expand our reach.


Forward-Looking Statements

This press release contains forward-looking statements. Readers are cautioned that such statements are only predictions and involve risks and uncertainties that could cause actual events or results to differ materially.


For more information, visit our website:



bottom of page